Antisense antibacterial compounds

Reed Pifer; David E Greenberg

doi:10.1016/j.trsl.2020.06.001

Antisense antibacterial compounds

Transl Res. 2020 Sep:223:89-106. doi: 10.1016/j.trsl.2020.06.001. Epub 2020 Jun 6.

Authors

Reed Pifer¹, David E Greenberg²

Affiliations

¹ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
² Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: David.Greenberg@UTSouthwestern.edu.

PMID: 32522669
DOI: 10.1016/j.trsl.2020.06.001

Abstract

Extensive antibiotic use combined with poor historical drug stewardship practices have created a medical crisis in which once treatable bacterial infections are now increasingly unmanageable. To combat this, new antibiotics will need to be developed and safeguarded. An emerging class of antibiotics based upon nuclease-stable antisense technologies has proven valuable in preclinical testing against a variety of bacterial pathogens. This review describes the current state of development of antisense-based antibiotics, the mechanisms thus far employed by these compounds, and possible future avenues of research.

Keywords: Antibiotic resistance; Antibiotics; Antisense; PPMOs; Peptide-conjugated phosphorodiamidate morpholino oligomers.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Animals
Anti-Bacterial Agents / pharmacology*
Bacteria / drug effects
Drug Resistance, Microbial / drug effects
Drug Resistance, Microbial / genetics
Gene Transfer Techniques
Humans
RNA, Antisense / chemistry
RNA, Antisense / pharmacology

Substances

Anti-Bacterial Agents
RNA, Antisense